Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.83 USD | +3.51% | -4.25% | -7.49% |
03-19 | Transcript : Relmada Therapeutics, Inc., 2023 Earnings Call, Mar 19, 2024 | |
03-19 | Relmada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | - | Sales 2025 * | 3M 240M | Capitalization | 116M 9.25B |
---|---|---|---|---|---|
Net income 2024 * | -112M -8.97B | Net income 2025 * | -120M -9.61B | EV / Sales 2024 * | - |
Net cash position 2024 * | 203M 16.21B | Net cash position 2025 * | 124M 9.91B | EV / Sales 2025 * | -2.76 x |
P/E ratio 2024 * |
-1.25
x | P/E ratio 2025 * |
-1.62
x | Employees | 20 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.96% |
Latest transcript on Relmada Therapeutics, Inc.
1 day | +3.51% | ||
1 week | -4.25% | ||
Current month | -17.63% | ||
1 month | -16.56% | ||
3 months | +5.51% | ||
6 months | +28.09% | ||
Current year | -7.49% |
Managers | Title | Age | Since |
---|---|---|---|
Paolo Manfredi
FOU | Founder | 62 | 30/05/12 |
Sergio Traversa
CEO | Chief Executive Officer | 63 | - |
Maged Shenouda
DFI | Director of Finance/CFO | 59 | 11/11/15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 78 | 13/07/15 | |
Sergio Traversa
CEO | Chief Executive Officer | 63 | - |
Maged Shenouda
DFI | Director of Finance/CFO | 59 | 11/11/15 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.10% | 0 M€ | 0.00% | - | |
0.03% | 509 M€ | -.--% | ||
0.00% | 237 M€ | +2.89% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 3.83 | +3.51% | 80,013 |
25/04/24 | 3.7 | -4.15% | 85,873 |
24/04/24 | 3.86 | -1.28% | 114,592 |
23/04/24 | 3.91 | +1.03% | 143,632 |
22/04/24 | 3.87 | -3.25% | 178,128 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.49% | 116M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- RLMD Stock